31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Abstract

Analysis of B and T cell responses in non-small cell lung cancer (NSCLC) patients enrolled in a phase II trial of cyclophosphamide with allogenic DRibble vaccine (DPV-001

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

“…Data were also recently presented from the Keynote-045 phase III study of pembrolizumab, an anti-PD-1 antibody, vs. investigator’s choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) [ 70 , 71 ]. The study was stopped early based on a pre-specified interim analysis in which pembrolizumab demonstrated a significant improvement in overall survival (median 10.3 vs. 7.4, HR: .73, p = .0022).…”

“…In the non-randomized CheckMate 032 study, preliminary data have also been reported on the combination of nivolumab plus ipilimumab in metastatic urothelial carcinoma. At time of presentation the nivolumab (1 mg) combined with ipilimumab (3 mg) group had an overall response rate of 38.5%, while the nivolumab (3 mg) combined with ipilimumab (1 mg) and nivolumab monotherapy groups had overall response rates of 26% and 25.5%, respectively [ 70 ]. Overall, these results indicate that targeting the immune system shows significant promise for the treatment of metastatic urothelial carcinoma.…”

New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness

“…On a phase I/II study of the NK-targeted antibody lirilumab (a fully human mAb that blocks inhibitory KIRs on NK cells) in combination with nivolumab in advanced HNSCC demonstrated, in preliminary results, clinical benefit, with deep and durable responses in some patients. This combination demonstrated a manageable safety profile similar to that observed with nivolumab monotherapy (NCT01714739) ( 347 ).…”

“…These include a clinical trial for melanoma patients with low tumor infiltrating lymphocytes, an anti-PD-1 non-responsive phenotype. The combination of pembrolizumab with an intratumoral electroporation of a plasmid coding for interleukin 12 cDNA (pIL-12) showed a 40% clinical response with associated positive immune-based biomarker data and a safety profile (NCT02493361) ( 347 ), where the combination of pembrolizumab with the plasmid pIL-12 renders half of the patients responsive to the anti-PD-1. Another example that combines mAb with cytokines is a study of immune activation and antitumor activity in renal cancer of PEGylated human IL-10 (AM0010) in combination with pembrolizumab or nivolumab, the combinations were well tolerated, and CD8 + T cell activation was detected (NCT02009449) ( 348 ).…”

Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non‐muscle‐invasive disease

“…Studies of combination immunotherapy in metastatic bladder cancer are ongoing , with promising preliminary data from the non‐randomized CheckMate 032 (NCT01928394) study (combination ipilimumab 3 mg/nivolumab 1 mg vs nivolumab alone), suggesting an ORR of 38.5% in the combination group vs 25.5% in the monotherapy group .…”